The psychedelic space was dealt a huge blow when the FDA decided not to approve MDMA-assisted therapy for PTSD under Lykos’ proposal. Was the FDA fair to Lykos? And what are the next steps for Lykos and MAPS? In this episode, Joe interviews Rick Doblin, Ph.D.: founder and president of the Multidisciplinary Association for Psychedelic […]

The post The FDA, MDMA, and Public Perception: Was the FDA Fair to Lykos? appeared first on Psychedelics Today.

Previous articlePα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme
Next articleHow Shadow Work Can Be a Powerful Tool for Psychedelic Transformation